Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imunon ( (IMNN) ) has shared an announcement.
On July 21, 2025, IMUNON, Inc. announced a one-for-fifteen reverse stock split of its common stock, effective July 25, 2025, to meet Nasdaq’s minimum bid price requirement for continued listing. This move will reduce the number of outstanding shares from approximately 31.8 million to 2.1 million, with no fractional shares issued, and the stock will continue trading under the ticker symbol ‘IMNN’ with a new CUSIP number. The reverse stock split is expected to impact the company’s operations by maintaining its Nasdaq listing, which is crucial for its market presence and investor confidence.
The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that leverage the body’s natural mechanisms to generate safe, effective, and durable responses across various human diseases. The company is advancing its non-viral DNA technology through two main modalities: TheraPlas® for gene-based delivery of cytokines in treating solid tumors, and PlaCCine® for gene delivery of viral antigens to elicit strong immunological responses. IMUNON’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, and the company has also completed a first-in-human study of its COVID-19 booster vaccine.
Average Trading Volume: 12,658,861
Technical Sentiment Signal: Sell
Current Market Cap: $12.67M
For a thorough assessment of IMNN stock, go to TipRanks’ Stock Analysis page.